Hikma Pharmaceuticals Plc (LON:HIK) insider Ali Al-Husry bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were purchased at an average cost of GBX 2,138 ($27.91) per share, with a total value of £1,069,000 ($1,395,379.19).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.33% on Thursday, hitting GBX 2106.00. The stock had a trading volume of 608,842 shares. The firm’s 50-day moving average is GBX 2,234.47 and its 200-day moving average is GBX 2,234.82. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The company’s market cap is GBX 4.76 billion.

A number of equities research analysts recently commented on HIK shares. Barclays PLC reaffirmed an “overweight” rating and set a GBX 2,900 ($37.85) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 9th. Numis Securities Ltd reaffirmed a “hold” rating and set a GBX 2,660 ($34.72) target price on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, August 24th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a GBX 2,550 ($33.29) target price on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, August 23rd. Jefferies Group decreased their target price on Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a “buy” rating for the company in a report on Monday, September 12th. Finally, Citigroup Inc. downgraded Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) target price for the company. in a report on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of GBX 2,520.90 ($32.91).

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/hikma-pharmaceuticals-plc-hik-insider-ali-al-husry-acquires-50000-shares.html

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.